Company intelligence / Profile preview

Maculaser

Helsinki, Uusimaa, Finlandmaculaser.com ↗

Ownership: Private
Employees: ~15
Development stage: Preclinical

Overview

Maculaser has completed preclinical validation showing that its non-damaging, temperature-controlled laser treatment activates cellular healing responses in the retina. The company’s technology aims to prevent progression of blinding diseases like AMD and DME by enabling safe, patient-specific early intervention. Clinical trials are being prepared or initiated as of the most recent updates.

Therapeutic areas: Ophthalmology
Modalities: Device (temperature-controlled laser therapy)Non-pharmacological therapy (retinal heating)
Industry: Therapeutic Medical Devices

Partnerships

Member of PhotonMed EU-funded photonics initiative (€32M Chips Joint Undertaking project)

Beyond the preview

Go deeper on Maculaser.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maculaser.

Explore the full profile